Published 2 years ago

Oxford malaria vaccine data bodes well for effort to combat deadly disease

Summary by Ground News

New data on a malaria vaccine from Oxford University bodes well for global effort to combat the mosquito-borne disease that kills a child every minute. The only approved malaria vaccine Mosquirix, made by global biopharma company GSK, was recently endorsed by the WHO. The Oxford vaccine, called R21/Matrix-M, is likely more effective than Mosqirix. Results will be filed with the World Health Organisation later this month. A manufacturer has already been lined up to produce 200 million doses a year. They could cost less than $5 each, according to the researchers.

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year